- Home
- GMAB vs OWL Comparison
GMAB vs OWL Comparison
Compare GMAB & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- OWL
- Stock Information
- Founded
- GMAB 1999
- OWL 2020
- Country
- GMAB Denmark
- OWL United States
- Employees
- GMAB N/A
- OWL N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- OWL Investment Managers
- Sector
- GMAB Health Care
- OWL Finance
- Exchange
- GMAB Nasdaq
- OWL Nasdaq
- Market Cap
- GMAB 15.0B
- OWL 12.9B
- IPO Year
- GMAB N/A
- OWL N/A
- Fundamental
- Price
- GMAB $21.80
- OWL $24.50
- Analyst Decision
- GMAB Buy
- OWL Buy
- Analyst Count
- GMAB 8
- OWL 13
- Target Price
- GMAB $43.00
- OWL $24.29
- AVG Volume (30 Days)
- GMAB 1.1M
- OWL 5.5M
- Earning Date
- GMAB 02-12-2025
- OWL 02-06-2025
- Dividend Yield
- GMAB N/A
- OWL 2.94%
- EPS Growth
- GMAB 14.35
- OWL N/A
- EPS
- GMAB 10.80
- OWL 0.05
- Revenue
- GMAB $2,967,926,227.00
- OWL $2,158,101,000.00
- Revenue This Year
- GMAB $32.03
- OWL $28.38
- Revenue Next Year
- GMAB $16.97
- OWL $29.28
- P/E Ratio
- GMAB $19.02
- OWL $467.16
- Revenue Growth
- GMAB 17.75
- OWL 32.15
- 52 Week Low
- GMAB $19.85
- OWL $15.18
- 52 Week High
- GMAB $31.88
- OWL $25.03
- Technical
- Relative Strength Index (RSI)
- GMAB 54.72
- OWL 59.65
- Support Level
- GMAB $19.89
- OWL $21.94
- Resistance Level
- GMAB $21.26
- OWL $24.30
- Average True Range (ATR)
- GMAB 0.42
- OWL 0.66
- MACD
- GMAB 0.02
- OWL 0.10
- Stochastic Oscillator
- GMAB 80.08
- OWL 92.42
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About OWL Blue Owl Capital Inc.
Blue Owl Capital Inc is an alternative asset management firm. The Company deploys private capital across Credit, GP Strategic Capital, and Real Estate platforms on behalf of institutional and private wealth clients. The Company conducts its operations through Blue Owl Capital Holdings LP ("Blue Owl Holdings") and Blue Owl Capital Carry LP ("Blue Owl Carry"). Its investor base includes a diversified mix of institutional investors, including public and private pension funds, endowments, foundations, family offices, private banks, high-net-worth individuals, asset managers, and insurance companies. The Company generates substantially all of its revenues in the United states.